BACKGROUND: Patients with cystic fibrosis with the same mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene differ widely in survival suggesting other factors have a substantial role in mortality. OBJECTIVE: To determine if the genotype distribution of variants in three putative cystic fibrosis modifier genes (tumour necrosis factor alpha (TNFalpha), transforming growth factor beta1 (TGFbeta1) or mannose-binding lectin (MBL2)) differed among patients with cystic fibrosis grouped according to age and survival status. METHODS: Genotypes of four variants (TNFalpha-238, TNFalpha-308, TGFbeta1-509 and MBL2 O) were determined in three groups of Caucasians from a single medical centre: 101 children with cystic fibrosis (aged <17 years; mean age 9.4 years), 115 adults with cystic fibrosis (aged > or =17 years; mean age 30.8 years) and 38 non-surviving adults with cystic fibrosis (21 deceased and 17 lung transplant after 17 years of age). Genotypes of 127 healthy Caucasians in the same geographical region were used as controls. Kaplan-Meier and Cox hazard regression were used to evaluate the genotype effect on cumulative survival. RESULTS: Genotype frequencies among adults and children with cystic fibrosis differed for TNFalpha-238 (G/G vs G/A; p = 0.022) and MBL2 (A/A vs O/O; p = 0.016). When adults with cystic fibrosis were compared to non-surviving adults with cystic fibrosis, genotype frequencies of both genes differed (TNFalpha-238G/G vs G/A; p = 0.0015 and MBL2: A/A vs O/O; p = 0.009). The hazard ratio for TNFalpha-238G/G vs G/A was 0.25 (95% CI 0.06 to 1.0, p = 0.04) and for MBL2 O/O vs A/A or A/O was 2.5 (95% CI 1.3 to 4.9, p = 0.007). CONCLUSIONS: TNFalpha-238 G/A and MBL2 O/O genotypes appear to be genetic modifiers of survival of cystic fibrosis.
BACKGROUND:Patients with cystic fibrosis with the same mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene differ widely in survival suggesting other factors have a substantial role in mortality. OBJECTIVE: To determine if the genotype distribution of variants in three putative cystic fibrosis modifier genes (tumour necrosis factor alpha (TNFalpha), transforming growth factor beta1 (TGFbeta1) or mannose-binding lectin (MBL2)) differed among patients with cystic fibrosis grouped according to age and survival status. METHODS: Genotypes of four variants (TNFalpha-238, TNFalpha-308, TGFbeta1-509 and MBL2 O) were determined in three groups of Caucasians from a single medical centre: 101 children with cystic fibrosis (aged <17 years; mean age 9.4 years), 115 adults with cystic fibrosis (aged > or =17 years; mean age 30.8 years) and 38 non-surviving adults with cystic fibrosis (21 deceased and 17 lung transplant after 17 years of age). Genotypes of 127 healthy Caucasians in the same geographical region were used as controls. Kaplan-Meier and Cox hazard regression were used to evaluate the genotype effect on cumulative survival. RESULTS: Genotype frequencies among adults and children with cystic fibrosis differed for TNFalpha-238 (G/G vs G/A; p = 0.022) and MBL2 (A/A vs O/O; p = 0.016). When adults with cystic fibrosis were compared to non-surviving adults with cystic fibrosis, genotype frequencies of both genes differed (TNFalpha-238G/G vs G/A; p = 0.0015 and MBL2: A/A vs O/O; p = 0.009). The hazard ratio for TNFalpha-238G/G vs G/A was 0.25 (95% CI 0.06 to 1.0, p = 0.04) and for MBL2 O/O vs A/A or A/O was 2.5 (95% CI 1.3 to 4.9, p = 0.007). CONCLUSIONS:TNFalpha-238 G/A and MBL2 O/O genotypes appear to be genetic modifiers of survival of cystic fibrosis.
Authors: M S Muhlebach; S L MacDonald; B Button; J J Hubbard; M L Turner; R C Boucher; D C Kilpatrick Journal: Clin Exp Immunol Date: 2006-08 Impact factor: 4.330
Authors: Nicole Mayer-Hamblett; Margaret Rosenfeld; Julia Emerson; Christopher H Goss; Moira L Aitken Journal: Am J Respir Crit Care Med Date: 2002-08-15 Impact factor: 21.405
Authors: Gerald T O'Connor; Hebe B Quinton; Terry Kneeland; Richard Kahn; Thomas Lever; Joanne Maddock; Priscilla Robichaud; Mark Detzer; Donald R Swartz Journal: Pediatrics Date: 2003-04 Impact factor: 7.124
Authors: R Sharma; V G Florea; A P Bolger; W Doehner; N D Florea; A J Coats; M E Hodson; S D Anker; M Y Henein Journal: Thorax Date: 2001-10 Impact factor: 9.139
Authors: W Kaluza; E Reuss; S Grossmann; R Hug; R E Schopf; P R Galle; E Maerker-Hermann; T Hoehler Journal: J Invest Dermatol Date: 2000-06 Impact factor: 8.551
Authors: Cyntia Aac Coutinho; Fernando Al Marson; Aline Rb Marcelino; Luciana C Bonadia; Marcelo P Carlin; Antonio F Ribeiro; Jose D Ribeiro; Carmen S Bertuzzo Journal: Int J Mol Epidemiol Genet Date: 2014-05-29
Authors: Franziska M Gisler; Thomas von Kanel; Richard Kraemer; André Schaller; Sabina Gallati Journal: Eur J Hum Genet Date: 2012-08-15 Impact factor: 4.246
Authors: Ruslan Dorfman; Andrew Sandford; Chelsea Taylor; Baisong Huang; Daisy Frangolias; Yongqian Wang; Richard Sang; Lilian Pereira; Lei Sun; Yves Berthiaume; Lap-Chee Tsui; Peter D Paré; Peter Durie; Mary Corey; Julian Zielenski Journal: J Clin Invest Date: 2008-03 Impact factor: 14.808
Authors: Kathryn E McDougal; M Daniele Fallin; David R Moller; Zhimin Song; David J Cutler; Lori L Steiner; Garry R Cutting Journal: J Invest Dermatol Date: 2009-02-19 Impact factor: 8.551
Authors: Kathryn E McDougal; Deanna M Green; Lori L Vanscoy; M Daniele Fallin; Michael Grow; Suzanne Cheng; Scott M Blackman; J Michael Collaco; Lindsay B Henderson; Kathleen Naughton; Garry R Cutting Journal: Eur J Hum Genet Date: 2010-01-13 Impact factor: 4.246